Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 0%
Sell 13%
Strong Sell 0%

Bulls say

Sionna Therapeutics is poised for success as they have a unique approach to treating cystic fibrosis, a strong leadership team, and support from the CF community. With their promising early results and ongoing clinical trials, the company has the potential to make significant advancements in the treatment of this life-threatening genetic disease. While competition exists, their high target price and the backing of the CF community suggest a positive outlook for the company's future financial performance.

Bears say

Sionna Therapeutics is a clinical-stage biopharmaceutical company that is focused on developing novel treatments for cystic fibrosis patients. Despite having a diverse portfolio of candidates and a differentiated approach to CF treatment, the company faces significant financial risks and will continue to incur losses for the foreseeable future. While Sionna's management has laid out a clear regulatory roadmap, the company will likely need to raise additional capital, which could have a dilutive impact on shareholder value. Furthermore, Sionna's potential drugs will need to compete with already established treatments from Vertex, and may not fully address the needs of all CF patients. Overall, the financial risks and competitive landscape suggest a negative outlook for Sionna's stock.

SION has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 8 analysts, SION has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.